Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0G1YO
|
|||
Former ID |
DCL000411
|
|||
Drug Name |
GSK1521498
|
|||
Synonyms |
GSK-1521498; GSK-1521498B
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Obesity [ICD-11: 5B81; ICD-10: E66; ICD-9: 278] | Phase 1 | [1] | |
Company |
GlaxoSmithKline
|
|||
Structure |
Download2D MOL |
|||
Formula |
C24H20F2N4
|
|||
Canonical SMILES |
C1C(CC2=CC=CC=C21)NCC3=C(C=C(C=C3F)C4=CC(=CC=C4)C5=NC=NN5)F
|
|||
InChI |
1S/C24H20F2N4/c25-22-11-19(15-6-3-7-18(8-15)24-28-14-29-30-24)12-23(26)21(22)13-27-20-9-16-4-1-2-5-17(16)10-20/h1-8,11-12,14,20,27H,9-10,13H2,(H,28,29,30)
|
|||
InChIKey |
WIEDUMBCZQRGSY-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 1007573-18-3
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Opioid receptor mu (MOP) | Target Info | Agonist | [1], [2] |
KEGG Pathway | Neuroactive ligand-receptor interaction | |||
Estrogen signaling pathway | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Enkephalin release | ||||
Pathway Interaction Database | IL4-mediated signaling events | |||
Reactome | Peptide ligand-binding receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | TCR Signaling Pathway | |||
GPCRs, Class A Rhodopsin-like | ||||
Peptide GPCRs | ||||
Opioid Signalling | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2011). | |||
REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.